Navigation Links
Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
Date:12/10/2007

Phase 2 clinical trial in patients with ovarian cancer. SNS-032, Sunesis' potent and selective inhibitor of CDKs 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in chronic lymphocytic leukemia and multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and receptor tyrosine kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the potential safety and efficacy of SNS-595 and SNS-032 and planned additional clinical testing and development efforts. Words such as "look forward," "designed," "believe," "appears" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risk
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 2014: Daily fruit consumption cuts the risk of cardiovascular ... presented at ESC Congress today by Dr Huaidong Du ... follow-up study of nearly 0.5 million people in the ... ate, the more their risk of CVD declined. , ... and stroke, is the leading cause of death worldwide. ...
(Date:9/1/2014)... Springs, LA (PRWEB) September 01, 2014 ... Intervention Instructor training, Derek is currently pursuing counselor certification ... able to advance through the CPI training program as ... states "and I have grown both personally and professionally. ... permanently recover, I am competently able to do so. ...
(Date:9/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... GLOBAL MARKETS , the global market for blood-brain barrier ... expected to reach $38.7 million in 2014. This is ... which is equivalent to 64.9% compound annual growth rate ... segment is forecasted to grow at a CAGR of ...
(Date:9/1/2014)... In honor of National Take Your Cat to the ... Referral Center of Minnesota (AERC) is offering a few reasons why ... , Many people don’t take their cat to the vet because ... they wouldn’t decide not to take their kid to dentist because ... goes for pets. Just like people want their loved ones to ...
(Date:9/1/2014)... Registration is now open for the 4th Annual Harmon Meadow ... held on Sunday, September 21, 2014. The event will be ... Secaucus, New Jersey. All proceeds from the race will benefit ... a sense of self, restoring the family unit, and restoring ... General registration is $30 with special pricing for veterans, military ...
Breaking Medicine News(10 mins):Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2
... infections of the brain, which can cause epileptic ... bordering southwestern states, Loyola University Health System researchers ... of the population may have the infection, neurocysticercosis. ... "remains a serious health concern, especially among the ...
... of a nationwide recession, a genetics research laboratory on Rutgers, ... continued success of the Rutgers University Cell and ... as a world leader in human disease and genome studies, ... and foundation grants that benefit the economy throughout the region. ...
... therapy, study found , WEDNESDAY, April 14 (HealthDay News) ... for developing blood clots, especially if they,re undergoing hormone ... it is important to consider thromboembolic [blood-clotting] side effects ... require endocrine treatment," said Mieke van Hemelrijck, lead author ...
... ... the increasing need for qualified nurses, Medi-Smart.com -- a site providing nursing education resources ... and feel designed to enhance user navigation, Medi-Smart now offers downloadable guides, videos, infographics, ... ...
... ... irritable bowel syndrome (IBS). Dr. David Blyweiss in Boca Raton, FL finds that diet and ... ... population suffers from the abdominal discomfort and altered bowel habits of the puzzling functional disorder ...
... ... PLM technologies, including expanding DesignState capablities as well as offering productized services for PLM. ... CEO and brought in Richard Haner, formerly a partner at Centerpoint Ventures, as Company Chairman. ... (PRWEB) April 14, ...
Cached Medicine News:Health News:Tapeworm brain infection 'serious health concern' 2Health News:Lab that probes genetic clues to disease is poised for major expansion 2Health News:Lab that probes genetic clues to disease is poised for major expansion 3Health News:Prostate Cancer Patients at Higher Risk of Blood Clots 2Health News:Prostate Cancer Patients at Higher Risk of Blood Clots 3Health News:Medi-Smart.com's New Look and Expanded Resources Meet Growing Nursing Employment Needs 2Health News:Dr. David Blyweiss Announces New IBS Relief Protocol 2Health News:Dr. David Blyweiss Announces New IBS Relief Protocol 3Health News:Zero Wait-State Announces New Leadership Team and Strategic Focus 2Health News:Zero Wait-State Announces New Leadership Team and Strategic Focus 3
(Date:8/30/2014)... Mass. , Aug. 30, 2014  Boston ... its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) ... clinical trial investigating vagus nerve stimulation (VNS) for ... M.D., Ph.D., Professor of Therapeutics and Cardiology and ... Institut National de la Sante et de la ...
(Date:8/29/2014)... -- Market Research Report on Global and Chinese ... and in-depth market survey on Global and ... firstly reviews the basic information of X-Ray Crystallography ... The report then explores global and China,s top ... specification, capacity, Production value, and market share etc. ...
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... Leaders (KOLs) can be the difference between a product,s ... to effectively map and stratify KOL targets – and ... build the type of strong relationships upon which successful ... research, savvy pharma companies have identified internal inconsistencies in ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5Implementing a Strategic Thought Leader Management & Engagement System 2
... Medical Systems (NYSE: VAR ), a world ... first education center in India to train medical physicists ... systems. The center in Mumbai, equipped ... system for radiotherapy treatment simulations, will enable the country,s ...
... RIVER, Mass., Sept. 1, Millstone Medical Outsourcing ... corporate website at www.millstonemedical.com .  With expanded ... with additional information about Millstone Medical,s services, commitment ... site,s design was intended to mirror the company,s ...
Cached Medicine Technology:Varian Medical Systems Establishes Radiotherapy Training Center in Mumbai, India 2Millstone Medical Outsourcing Launches New, Improved Company Website 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... AliMed® Turnbuckle Ankle Orthosis enables ... torque at the ankle joint to ... The splint features a pair of ... and eversion/inversion simultaneously. Simply adjust the ...
Softsplint after bunion surgery. Hook-and-loop closure. Maintains hallux positioning and metatarsophalangeal alignment. Washable....
... As a prophylaxis for deep vein thrombosis, ... combination of graduated sequential compression and rapid ... formation by increasing venous ejection while producing ... System includes a pump with tube assembly ...
Medicine Products: